Your browser doesn't support javascript.
loading
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Sinha, Meenal; Betts, Courtney; Zhang, Li; Griffith, Madeline J; Solman, Isabelle; Chen, Brandon; Liu, Eric; Tamaki, Whitney; Stultz, Jacob; Marquez, Jaqueline; Sivagnanam, Shamilene; Cheung, Alexander; Pener, Denise; Fahlman, Anne; Taber, Erin; Lerner, Kimberly; Crocker, Matthew; Todd, Kendra; Rajagopalan, Brindha; Ware, Clarisha; Bridge, Mark; Vo, Johnson; Dragomanovich, Hannah; Sudduth-Klinger, Julie; Vaccaro, Gina; Lopez, Charles D; Tempero, Margaret; Coussens, Lisa M; Fong, Lawrence.
Afiliação
  • Sinha M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Betts C; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
  • Zhang L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Griffith MJ; Department of Biostatistics, University of California, San Francisco, California, USA.
  • Solman I; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Chen B; AbbVie, Irvine, California, USA.
  • Liu E; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Tamaki W; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Stultz J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Marquez J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Sivagnanam S; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Cheung A; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
  • Pener D; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Fahlman A; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Taber E; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Lerner K; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Crocker M; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Todd K; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Rajagopalan B; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Ware C; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Bridge M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Vo J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Dragomanovich H; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Sudduth-Klinger J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Vaccaro G; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Lopez CD; Medical Oncology, Providence Portland Medical Center, Portland, Oregon, USA.
  • Tempero M; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
  • Coussens LM; Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Fong L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
J Immunother Cancer ; 11(1)2023 01.
Article em En | MEDLINE | ID: mdl-36593070

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Carcinoma Ductal Pancreático / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Carcinoma Ductal Pancreático / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article